CKD Bio Corp
KRX:063160
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| KR |
|
CKD Bio Corp
KRX:063160
|
105.7B KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
879B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
576.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
256.6B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
233.8B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
222.9B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.7B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.3B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.9B USD |
Loading...
|
Market Distribution
| Min | -646.5% |
| 30th Percentile | 12.8% |
| Median | 19.7% |
| 70th Percentile | 32.2% |
| Max | 54 001.3% |
Other Profitability Ratios
CKD Bio Corp
Glance View
CKD Bio Corp. engages in the development and manufacture of active pharmaceutical ingredients. The company is headquartered in Seoul, Seoul. The company went IPO on 2001-12-11. The firm mainly provides antibiotic ingredients, consisting of demethylchlortetracyclines (DMCTs) and rifampicins. The company also provides immunosuppressive agents, including cyclosporin and tacrolimus; remedies for diabetes, such as acarbose, and potassium clavulanate used for beta-lactam inhibitors. The firm distributes its products within domestic market and to overseas markets, such as America, China, Europe, Africa, Southeast Asia, Latin America and the Middle East.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for CKD Bio Corp is 20.1%, which is above its 3-year median of 13.4%.
Over the last 3 years, CKD Bio Corp’s Gross Margin has increased from 12.7% to 20.1%. During this period, it reached a low of 4.3% on Sep 30, 2023 and a high of 21% on Mar 31, 2025.
